Please assess the completion status of the following clinical trial:

Trial Title: ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male, non-smoker, 21 - 75 years of age inclusive.~2. Female, non-smoker, 40 - 75 years of age inclusive.~3. Post-menopausal women, as defined by lack of menses for at least 2 years and age \> 55, OR history of documented bilateral surgical oophorectomy, confirmed with an elevated follicle-stimulating hormone (FSH) at screening.~4. HDL concentration (≤ 50 mg/dl women, ≤ 40mg/dl men)~5. TG concentration 150-500 mg/dl, inclusive~6. Ability to give informed consent~Exclusion Criteria:~1. Subject has history of diabetes mellitus, active hepatitis, gall bladder disease, gastric bypass surgery, or clinically significant abnormalities on screening (prestudy) physical examination or laboratory tests.~2. Screening laboratory tests with hematocrit \<30%, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 2X upper limit of normal, abnormal thyroid-stimulating hormone (TSH), fasting glucose ≥126 mg/dl.~3. Renal impairment with creatinine clearance \< 80 ml/min.~4. Treatment within the last 6 months with drugs known to alter lipid metabolism including beta blockers, thiazide diuretics, bile acid resins, ezetimibe, fibrates, niacin, and fish oils (see Appendix 1). Washout of fibrates is not permitted.~5. Treatment with drugs known to interact with ABT-335, e.g., warfarin (see Appendix 1).~6. Treatment with HMG CoA reductase inhibitors (statins) within the past 4 weeks (see Appendix 1).~7. History of allergy to egg or soy products.~8. History of coronary heart disease (CHD), stroke or revascularization procedure in the six months prior to Visit 1.~9. Current or recent history (past 12 months) of drug abuse or alcohol abuse. Alcohol abuse will be defined as \>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor).~10. Participation in another clinical trial or exposure to any investigational agent within 30 days before visit 1.~11. Individual has a condition the Principal Investigator believes would interfere with his/her ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Abt-335 (Type: EXPERIMENTAL): ABT-335 (choline fenofibrate)

Based on this trial design, predict the completion outcome and termination type (if applicable).